期刊论文

中文

肿瘤防治研究

1000-8578

2011

38

3

243-246

10.3971/j.issn.1000-8578.2011.03.001

江苏省高校自然科学研究计划基金资助项目（08KJD320007）；

本校为第一机构

目的 探讨以RNA干扰(RNA interference,RNAi)技术靶向stathmin和mdr1基因逆转卵巢癌细胞紫杉醇耐药的可行性. 方法 分别构建靶向stathmin和mdr1基因的质粒:pGU6-GFP-neo-ST-MN1和pGU6-GFP-neo-MDR1;将质粒转染到卵巢癌紫杉醇耐药细胞株SKOV3/TAX. Real-time RT-PCR检测stathminm和mdr1的mRNA变化;Western blot检测其蛋白表达变化;荧光显微镜检测细胞凋亡情况;CCK-8法分析细胞对紫杉醇的敏感度. 结果 Real-time RT-PCR及Western blot显示 pGU6-GFP-neo-MDR1质粒对mdr1基因, pGU6-GFP-STMN1-294shRNA质粒对stathmin基因在mR-NA水平和蛋白水平均有明显抑制(P

Objective To investigate the feasibility of reversing Paclitaxel resistance by RNA interference（RNAi）-mediated suppression of stathmin and mdr1 genes in ovarian cancer cells.Methods Two different plasmids with short hairpin RNAs（shRNAs） targeting stathmin and mdr1 were constructed respectively：pGU6-GFP-neo-STMN1 and pGU6-GFP-neo-MDR1.Then they were transfected into a Paclitaxel-resistant ovarian cancer cell line（SKOV3/TAX）.The expression levels of mRNA and protein of stathmin and mdr1 were evaluated by Real-time RT-PCR and Western blot a...